Health Catalyst

Accelerating AI Adoption And Digital Transformation Will Expand Healthcare Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 9 Analysts

Published

09 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$9.00

63.6% undervalued

21 Aug

US$3.28

-54.9%

12.3%

Author's Valuation

US$9.0

63.6% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$9.0

63.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.41%

Healthtech revenue growth rate

4.12%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.82%

Calculation

US$46.99m

Earnings '28

27.66x

PE Ratio '28

US$1.30b

Market Cap '28

US$1.30b

Market Cap '28

108.87m

No. shares '28

US$11.94

Share Price '28

US$11.94 Share Price '28

Discounted to 2025 @ 9.87% p.a.

US$9.00

Fair Value '25